• Field Medical

  Led · Series B · Jul 2025

  Field Medical develops the FieldForce™ Ablation System, a next-generation pulsed field ablation (PFA) platform designed for transmural lesion creation and targeted ventricular tachycardia (VT) ablation. The system pairs breakthrough catheter design with proprietary FieldBending™ energy to enable rapid, targeted ablation. The device is investigational and limited to investigational use under U.S. law. The company plans to use new funding to initiate its pivotal VERITAS trial and to advance FieldForce development while expanding clinical and regulatory capabilities. Field Medical received Breakthrough Device Designation in 2024 and was selected for the FDA TAP Pilot Program for its VT indication. With strong pilot data presented at Heart Rhythm 2025, the company is positioning to address an underpenetrated VT market. Field Medical is developing next-generation pulsed field ablation (PFA) technologies, centered on the FieldForce™ Ablation System and its built-for-purpose, contact-force focal PFA catheter. The system enables an instantaneous ablation workflow with therapy delivered in a fraction of a second and is powered by the company's proprietary FieldBending™ technology that delivers brief, high-intensity electric fields. Field Medical positions the System as a single advanced solution for a full spectrum of cardiac arrhythmias, including ventricular tachycardia (VT) and atrial fibrillation (AF). The company is completing two pilot studies (VCAS for VT and Field PULSE for AF) and advancing toward VERITAS, a planned pivotal trial focused on VT. Financially, Field Medical closed a $40 million Series A that includes $20 million in new capital and the conversion of $20 million in seed-round debt to support clinical programs, commercial development, and operational scale-up. Founded in 2022, the company received FDA Breakthrough Device Designation and was included in the TAP Pilot Program in 2024. Field Medical, Inc. is described as an emerging leader in cardiac catheter ablation and is based in Cardiff-by-the-Sea, California. The company operates in the cardiac catheter ablation space. Field Medical closed an oversubscribed seed round totaling $14M. The financing was structured as convertible notes. The seed was led by private investors and included multiple strategic investors. The article did not disclose revenue, user metrics, prior rounds, founding year, or additional financial terms.

• Amplitude Vascular Systems

  Participated · Series B · Jan 2025

  Amplitude Vascular Systems (AVS) develops the PULSE IVL™ (Pulse Intravascular Lithotripsy™) platform, an investigational device for treating severely calcified arterial disease. The PIVL™ device is designed to improve deliverability, crossability, and efficiency in challenging peripheral, coronary, and carotid cases by using a mechanism that eliminates electrical emitters. AVS is preparing a U.S. peripheral commercial launch and is conducting multiple IDE trials, including a POWER PAD II U.S. peripheral IDE that began enrolling in October 2024. POWER PAD II is a prospective, single-arm, multi-center study that will enroll up to 120 patients across 20 U.S. sites, with enrollment expected to complete mid-2025. The company is partnering with the Jacobs Institute for a U.S. carotid IDE trial and also plans a U.S. coronary IDE study. AVS is based in Boston, MA and is backed by investors including BioStar Capital, Cue Growth Partners, and others; the PULSE IVL™ System remains investigational and is not yet cleared for commercial distribution. Amplitude Vascular Systems develops the Pulse IVL system, which generates pulsatile pressure waves delivered through a balloon to create multi-directional fractures in intravascular calcium and thereby increase vessel compliance. The device generates energy outside the body and amplifies it without electrodes or lasers in the balloon, yielding a low crossing profile, greater flexibility, and a non-compliant balloon designed to expand vessels without traumatizing healthy tissue. Pulse therapy is delivered at higher frequency and uniformly along the balloon length, aiming to reduce procedure time and the need for ancillary devices. AVS completed a first-in-human study showing benefits in calcific femoropopliteal arteries and recently received FDA IDE approval to begin a 20-site pivotal peripheral trial in the U.S., with a target enrollment of 120 patients. The company plans clinical testing in coronary and carotid indications, aims for a first commercial peripheral product in early 2026, and is developing an AI-powered “Smart IVL” to inform operators of treatment success in real time. Financially, the company raised over $250,000 in non-dilutive grants during early work, a $1.5M initial funding round to transfer technology from the University of Michigan, and secured $29M in a Series B in late 2023.

• AVS

  Led · Series B · Apr 2023

  AVS is an early-stage medical device company developing the PULSE IVL System, a balloon-based pulsatile intravascular lithotripsy (PIVL) platform to treat severely calcified arterial disease. The device uses pressure waves in frequent bursts to gently shatter calcium and expand narrowed vessels through a single device. AVS completed a first-in-human POWER PAD I feasibility trial, enrolling patients and collecting positive 30-day follow-up in September 2022. The company plans to continue peripheral clinical trials and advance preclinical work toward an expanded coronary indication with the goal of U.S. approval for both applications. AVS closed an additional $8.8 million to bring its Series B to $28.8 million, funding that will support those clinical and preclinical efforts. The company was founded in 2018 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D. AVS is developing the PULSE IVL System, a balloon-based pulsatile intravascular lithotripsy platform that uses pressure waves in frequent bursts to shatter vascular calcium and expand calcified arteries with a single device. The company is advancing a peripheral PIVL device toward clinical trials and is conducting preclinical development on a coronary PIVL device. Early clinical work includes the POWER PAD I first-in-human study, which reported enrollment, successful treatment, and positive 30-day follow-up with patients noting reduced leg pain and improved walking ability. AVS was founded in 2018 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D., and the company is referenced from Boston. The PULSE Peripheral IVL System remains in development and is not yet cleared for commercial distribution. Management has signaled plans to accelerate trial timelines and development activities with new funding.

No current team members are available.